Acer Therapeutics is developing therapies for patients with serious, ultra-rare diseases with critical unmet need.

Acer Therapeutics is committed to delivering life-changing benefits to patients who lack treatment options

Lead Program

We are working to obtain FDA approval for celiprolol for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the US.

Latest News

Dec. 20, 2016 –¬†Acer Therapeutics Announces the Formation of its Scientific Advisory Board (SAB).

Dec. 13, 2016 –¬†Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP.


We are developing ACER-001 as the first potential therapy for Maple Syrup Urine Disease (MSUD); and for Urea Cycle Disorders (UCD)